Grup de recerca de biomarcadors en càncer (GReBiC)
- Nombre de publicacions
- 495
Publicacions
-
Griguolo, G; Serna, G; Pascual, T; Fasani, R; Guardia, X; Chic, N; Pare, L; Pernas, S; Munoz, M; Oliveira, M; Vidal, M; Llombart-Cussac, A; Cortes, J; Galvan, P; Bermejo, B; Martinez, N; Lopez, R; Morales, S; Garau, I; Manso, L; Alarcon, J; Martinez, E; Villagrasa, P; Prat, A; Nuciforo, P
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
npj Precision Oncology 5 -. .
-
Bielsa S; Bernet A; Civit C; Acosta C; Manonelles A; Porcel JM
FluoroType® MTB in pleural fluid for diagnosing tuberculosis.
REVISTA CLINICA ESPANOLA 221 139-144. .
-
Morales Murillo, Serafin; Gasol Cudos, Ariadna; Veas Rodriguez, Joel; Canosa Morales, Carles; Melé Olivé, Jordi; Vilardell Villellas, Felip; Sanchez Guzman, Douglas Rene; Iglesias Martínez, Edelmiro; Salud Salvia, Antonieta
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer
BREAST 56 35-41. .
-
Murillo, SM; Cudos, AG; Rodriguez, JV; Morales, CC; Olive, JM; Villellas, FV; Guzman, DRS; Martinez, EI; Salvia, AS
Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
Future Science Oa 7 -. .
-
Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M; ExteNET Study Group
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
CLINICAL BREAST CANCER 21 80-917. .
-
Murillo, SM; Cudos, AG; Subirats, OP; Olive, JM; Morales, CC; Villellas, FV; Guzman, DRS; Rodriguez, JV; Galindo, AR
Axillary management after neoadjuvant chemotherapy in initially node positive early breast cancer
CANCER RESEARCH 81 -. .
-
Oliveira, M; Villagrasa, P; Ciruelos, E; Gavila, J; Cortegoso, A; Henao, F; Vega, E; Bofill, JS; Quiroga, V; Garcia-Estevez, L; Morales, S; Tolosa, P; Celiz, P; Farre, XG; Saura, C
Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather)
CANCER RESEARCH 81 -. .
-
Prat, A; Gavila, J; Pernas, S; Cruz, J; Saura, C; Nogales, E; Bermejo, M; Bofill, JS; Quiroga, V; Garcia-Estevez, L; Morales, S; Servitja, S; del Toro, R; Galvan, P; Chic, N; Martinez, D; Braso-Maristany, F; Canes, J; Pare, L; Ferrero-Cafiero, JM; Villagrasa, P
Solti-1804 HER2-PREDICT: A biomarker research study of DS8201-A-U301-U302 and-U303 trials
CANCER RESEARCH 81 -. .
-
Saura, C; Ciruelos, E; Vidal, M; Garrigos, L; Margeli, M; Morales, S; Gonzalez-Farre, X; Bofill, JS; Blancas, I; Gasent, JM; Lopez-Miranda, E; Godoy, A; Iglesias, M; Sanchez-Rovira, P; Hernao, F; Gallegos, I; Pulido, C; Alves, S; Branco, D; Passos-Coelho, J; Escriva-de-Romani, S; Ferrero-Cafiero, JM; Villagrasa, P; Prat, A
Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC)
CANCER RESEARCH 81 -. .
-
Schmid P; Sablin MP; Bergh J; Im SA; Lu YS; Martínez N; Neven P; Lee KS; Morales S; Pérez-Fidalgo JA; Adamson D; Gonçalves A; Prat A; Jerusalem G; Schlieker L; Espadero RM; Bogenrieder T; Huang DC; Crown J; Cortés J
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
BREAST CANCER RESEARCH 23 8-8. .
-
Porcel JM
Review of Medical Therapy in the Emergency Department.
REVISTA CLINICA ESPANOLA 221 68-68. .
-
Cudos, AG; Murillo, SM; Subirats, OP; Villellas, FV; Guzman, DRS; Morales, CC; Olive, JM; Sanchez, AV; Ortega, JFC
Relapse pattern after neoadjuvant treatment in early breast cancer
ANNALS OF ONCOLOGY 32 437-437. .
